Finished product reference
Dextromethorphan / Guaifenesin / Pseudoephedrine
Syrup · Oral · 15 mg/200 mg/30 mg/5mL · 120 mL
- List code
- 53161
- Pharmacologic class
- Combination cough and cold preparation (antitussive + expectorant + sympathomimetic decongestant)
What it is and how it works
Dextromethorphan is a morphinan derivative without opioid analgesic activity that suppresses the cough centre in the medulla; guaifenesin is an expectorant intended to loosen bronchial secretions; pseudoephedrine is a sympathomimetic that constricts nasal blood vessels and reduces congestion.
Indications
Short-term symptomatic relief of cough with nasal and sinus congestion in colds and upper respiratory tract infections.
Contraindications
Concurrent or recent (within 14 days) MAOI therapy; severe hypertension or coronary artery disease; children below the age limits set by national guidance (cough and cold products are not recommended in young children).
Warnings and precautions
Use with caution in hypertension, cardiovascular disease, hyperthyroidism, diabetes, prostatic hypertrophy, glaucoma and in asthma or chronic productive cough. Dextromethorphan has potential for misuse and may cause serotonin syndrome with serotonergic drugs. Do not combine with other cold preparations containing the same ingredients.
Pregnancy
Avoid in pregnancy, particularly in the first trimester, unless advised by a doctor.
Storage and supply
Store below 25 °C, protected from light.
Source: reference summary prepared from the EU SmPC/EPAR, BNF and WHO Model Formulary. The approved product information in Iran governs.
Reference information for professional sourcing and registration enquiries, not medical advice or a promotion. Drug information is condensed from US FDA prescribing information (public domain, via openFDA and DailyMed) and does not replace the product’s approved labelling in Iran. Availability, origin and documentation are confirmed per enquiry.
Tell us the quantity, the market and the timing.
Send the molecule or ingredient, the specification and the destination. We reply from Tehran with the questions, the documents and the next step.